Ryvent Tablet
Pricing Report NDC 15370-130-10

View Wholesale Price per Unit, Acquisition Costs, and Historic Pricing Trends
Table of Contents
  1. Current Pricing Information
  2. Pricing History

Current Package Pricing Information

The latest wholesale acquisition cost for Ryvent (NDC 15370-130-10) is $7.73981 per EA. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Feb 19, 2025.

As a a human prescription drug provided by Carwin Pharmaceutical Associates, Llc, this medication is distributed in a 100 TABLET in 1 BOTTLE, PLASTIC configuration. The pricing data is derived from C/I - Chain or Independent Pharmacy surveys, reflecting the actual invoice prices paid by community pharmacies to drug wholesalers.

NADAC Pricing Summary

NADAC pricing snapshot for this package NDC

Acquisition Cost
$8.11672
Per EA

Pricing Unit
Per EA Pricing Unit
Indicates the billing unit (ML, GM or EA).
Effective Date
Feb 14, 2025
Billable Units
100 EA
Estimated Package Price
$811.67
Data Status
As of Feb 11, 2026
Pharmacy Source Pharmacy Type Indicator
Data collected from Chain/Independent pharmacy surveys.
C/I - Chain or Independent Pharmacy
Rate Classification Classification for Rate Setting
Indicates if the NDC is Brand (B) or Generic (G).
B-ANDA - Abbreviated New Drug Application
Package NDC
15370-130-10
Description
100 TABLET in 1 BOTTLE, PLASTIC
Pricing Methodology Explanation
The NADAC was carried forward from the previous file.
The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.

Historical Pricing Trends & Acquisition Cost Benchmarks

Since Dec 2018, the NADAC wholesale price for (NDC ) has moved within a range of $4.16596 to $8.11672 per EA. Over this 6 years and 2 months period, the pricing trend reflects the shifting acquisition costs reported by retail and chain pharmacies to the Centers for Medicare and Medicaid Services (CMS). The following interactive chart and historical table detail every recorded price adjustment based on these federal surveys.

Price Range
$4.1660 - $8.1167
Market Volatility
94.83% Variance
Latest Trend
4.64%
Date Unit Price Unit Source Method Rate
Feb 19, 2025 $7.73981 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Feb 14, 2025 $8.11672 EAC/I - Chain or Independent PharmacyCode 3, 6B-ANDA - Abbreviated New Drug Application
Feb 14, 2025 $8.11672 EAC/I - Chain or Independent PharmacyCode 4, 6B-ANDA - Abbreviated New Drug Application
Jan 22, 2025 $7.73021 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Dec 18, 2024 $7.73021 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Nov 20, 2024 $7.74316 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Oct 23, 2024 $7.74316 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application
Mar 01, 2024 $7.77331 EAC/I - Chain or Independent PharmacyCode 3, 6B-ANDA - Abbreviated New Drug Application
Mar 01, 2024 $7.77331 EAC/I - Chain or Independent PharmacyCode 4, 6B-ANDA - Abbreviated New Drug Application
Mar 03, 2023 $7.40315 EAC/I - Chain or Independent PharmacyCode 3, 6B-ANDA - Abbreviated New Drug Application
Mar 03, 2023 $7.40315 EAC/I - Chain or Independent PharmacyCode 4, 6B-ANDA - Abbreviated New Drug Application
Sep 09, 2022 $6.79188 EAC/I - Chain or Independent PharmacyCode 3, 6B-ANDA - Abbreviated New Drug Application
Sep 09, 2022 $6.79188 EAC/I - Chain or Independent PharmacyCode 4, 6B-ANDA - Abbreviated New Drug Application
Mar 03, 2022 $6.40750 EAC/I - Chain or Independent PharmacyCode 3, 6B-ANDA - Abbreviated New Drug Application
Mar 03, 2022 $6.40750 EAC/I - Chain or Independent PharmacyCode 4, 6B-ANDA - Abbreviated New Drug Application
Sep 15, 2021 $5.83024 EAC/I - Chain or Independent PharmacyCode 3, 6B-ANDA - Abbreviated New Drug Application
Sep 15, 2021 $5.83024 EAC/I - Chain or Independent PharmacyCode 4, 6B-ANDA - Abbreviated New Drug Application
Mar 12, 2021 $5.50023 EAC/I - Chain or Independent PharmacyCode 3, 6B-ANDA - Abbreviated New Drug Application
Mar 12, 2021 $5.50023 EAC/I - Chain or Independent PharmacyCode 4, 6B-ANDA - Abbreviated New Drug Application
Sep 22, 2020 $5.18894 EAC/I - Chain or Independent PharmacyCode 3, 6B-ANDA - Abbreviated New Drug Application
Sep 22, 2020 $5.18894 EAC/I - Chain or Independent PharmacyCode 4, 6B-ANDA - Abbreviated New Drug Application
Jan 10, 2020 $5.01347 EAC/I - Chain or Independent PharmacyCode 3, 6B-ANDA - Abbreviated New Drug Application
Jan 10, 2020 $5.01347 EAC/I - Chain or Independent PharmacyCode 4, 6B-ANDA - Abbreviated New Drug Application
Jan 03, 2019 $4.56173 EAC/I - Chain or Independent PharmacyCode 3, 6B-ANDA - Abbreviated New Drug Application
Jan 03, 2019 $4.56173 EAC/I - Chain or Independent PharmacyCode 4, 6B-ANDA - Abbreviated New Drug Application
Dec 19, 2018 $4.16596 EAC/I - Chain or Independent PharmacyCode 1, 6B-ANDA - Abbreviated New Drug Application

Pricing Methodology Legend

  • Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey.
  • Code 3: The NADAC based on survey data has been adjusted to reflect changes in published pricing, or as a result of an inquiry to the help desk.
  • Code 4: The NADAC was carried forward from the previous file.
  • Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.

Understanding NADAC Pricing Data

The National Average Drug Acquisition Cost (NADAC) is compiled by the Centers for Medicare and Medicaid Services (CMS). This data is derived from random monthly surveys of more than 60,000 pharmacies across all 50 states.

Important Price Distinction:

The prices listed on this page represent the wholesale invoice price paid by pharmacies to acquire the drug. This is NOT the retail price paid by consumers at the pharmacy counter. Final patient costs typically include pharmacy markups, professional dispensing fees, and insurance adjustments.

NADAC Pricing Data Last Updated on: July 08, 2026